Leptin: A Marker for AML Chemo-Sensitivity

Bone Marrow Supernatant Leptin as A Predictor of Chemotherapy Sensitivity in AML Patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07163728

Enrollment

Registered

2025-09-09

Start date

2025-08-01

Completion date

2026-12-31

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult, AML

Keywords

AML, Leptin, Chemotherapy sensitivity

Brief summary

Acute Myeloid Leukemia (AML) is a malignant clonal disorder of hematopoietic stem/progenitor cells, with a five-year survival rate of approximately 30%. Chemotherapy resistance and relapse remain major challenges. Increased bone marrow adipocytes contribute to AML cell drug resistance.This study found that elevated levels of the adipokine leptin enhance oxidative phosphorylation (OXPHOS) in AML cells, accompanied by increased mitochondrial reactive oxygen species (mtROS), which stimulates antioxidant capacity and thereby induces chemotherapy resistance. By establishing a correlation between leptin levels in bone marrow supernatant and clinical outcomes in AML patients, this research provides novel strategic insights for targeting drug resistance and improving prognostic evaluation.

Detailed description

In this prospective study, we will collect bone marrow supernatant samples from patients diagnosed with Acute Myeloid Leukemia (AML) to evaluate the levels of leptin. Our aim is to explore whether elevated leptin levels can serve as a predictive biomarker for poor treatment outcomes following standard chemotherapy regimens. The findings may help in stratifying patient risk and personalizing therapeutic approaches in AML treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

1. Clinical diagnosis aligns with the Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023); 2. All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study; 3. Patients participate in the study accompanied by family members and sign informed consent documents.

Exclusion criteria

1. Patients with concurrent malignancies requiring treatment; 2. Presence of infectious diseases, including SARS, viral hepatitis, or HIV/ AIDS; 3. Major surgery performed within the last 21 days; 4. Performance Status (PS) score \>3; 5. Severe liver or kidney dysfunction or serious infection; 6. Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.

Design outcomes

Primary

Measure	Time frame	Description
ORR	1 month	The primary endpoint of this study is the overall response rate (ORR) after Chemotherapy

Secondary

Measure	Time frame	Description
CR	1 month	The secondary endpoints is the complete remission (CR) rate after Chemotherapy
CRi	1 month	The secondary endpoints is the complete remission with incomplete blood count recovery (CRi) rate after Chemotherapy
PR	1 month	The secondary endpoints is the partial remission (PR) rate after Chemotherapy

Countries

China

Contacts

Primary ContactHuifang Huang

huanghuif@fjmu.edu.cn13365910318

Outcome results